1. Home
  2. NUV vs DMRA Comparison

NUV vs DMRA Comparison

Compare NUV & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Value Fund Inc.

NUV

Nuveen Municipal Value Fund Inc.

N/A

Current Price

$8.08

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Damora Therapeutics Inc. Common Stock

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$23.17

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUV
DMRA
Founded
1987
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NUV
DMRA
Price
$8.08
$23.17
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $46.78
AVG Volume (30 Days)
★ 1.3M
486.6K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 3.96%
N/A
EPS Growth
N/A
★ 121.48
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.02
$16.50
52 Week High
$9.26
$34.89

Technical Indicators

Market Signals
Indicator
NUV
DMRA
Relative Strength Index (RSI) 37.22 54.24
Support Level $8.05 $22.31
Resistance Level $8.34 $26.42
Average True Range (ATR) 0.09 1.85
MACD -0.03 0.12
Stochastic Oscillator 7.14 57.87

Price Performance

Historical Comparison
NUV
DMRA

About NUV Nuveen Municipal Value Fund Inc.

Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: